Amyloidosis natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Amyloidosis}}
{{Amyloidosis}}
{{CMG}} {{AE}}
{{CMG}} {{AE}} {{SHH}}
 
{{PleaseHelp}}


==Overview==
==Overview==
The complications of amyloidosis include [[hyposplenism]], [[malabsorption syndrome]], [[myopathy]], [[proximal renal tubular acidosis]] and [[renal failure]]. The severity of the disease depends on the organs that are affected.  When the [[heart]] and [[kidneys]] are involved, it may lead to [[organ failure]] and eventual death.


==Natural History==
==Natural History==


==Complications==
==Complications==
Possible complications of amyloidosis include:
 
* Hyposplenism
* [[Malabsorption syndrome]]
* [[Myopathy]]
* [[Proximal renal tubular acidosis]]
* [[Renal failure]]
* Vascular hemostatic disorder
* Chronic brain failure
* [[Nephrotic syndrome]]
* [[Myocarditis]]
* [[Restrictive cardiomyopathy]]
* [[Pulmonary fibrosis]]
* [[Autonomic neuropathy]]
* [[Pericardial effusion]]
* [[Congestive heart failure (patient information)|Congestive heart failure]]
* [[Endocrine failure]] (hormonal disorder)
* [[Respiratory failure]]
* [[Hypogonadic hypogonadism]]
* [[Death]]


==Prognosis==
==Prognosis==
The severity the disease depends on the organs that are affected.  When the heart and kidney are involved, it may lead to organ failure and death. Body-wide (systemic) involvement can lead to death in 1 to 3 years.
* The median survival of patients with AL amyloidosis is aproximately 3.8 years.
* In AL amyloidosis 27% of patients dying within 1 year from diagnosis.
* The major determinant of outcome in amyloidosis is the extent of cardiac involvement.
** Cardiac amyloidosis is the cause of death in 75% of the patients who died, including sudden death in 25%.


==References==
==References==
{{reflist|2}}
{{reflist|2}}


[[Category:Disease]]
[[Category:Medicine]]
[[Category:Rheumatology]]
 
[[Category:Cardiology]]
[[Category:Endocrinology]]
[[Category:Needs content]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}

Revision as of 14:26, 3 May 2018

Amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Primary amyloidosis
Secondary amyloidosis
Familial amyloidosis
Wild-type (senile) amyloidosis
Cardiac amyloidosis
Beta-2 microglobulin related amyloidosis
Gelsolin related amyloidosis
Lysozyme amyloid related amyloidosis
Leucocyte cell-derived chemotaxin 2 related amyloidosis
Fibrinogen A alpha-chain associated amyloidosis

Pathophysiology

Causes

Differentiating Amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Amyloidosis natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Amyloidosis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Amyloidosis natural history, complications and prognosis

CDC on Amyloidosis natural history, complications and prognosis

Amyloidosis natural history, complications and prognosis in the news

Blogs on Amyloidosis natural history, complications and prognosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Amyloidosis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]

Overview

Natural History

Complications

Prognosis

  • The median survival of patients with AL amyloidosis is aproximately 3.8 years.
  • In AL amyloidosis 27% of patients dying within 1 year from diagnosis.
  • The major determinant of outcome in amyloidosis is the extent of cardiac involvement.
    • Cardiac amyloidosis is the cause of death in 75% of the patients who died, including sudden death in 25%.

References


Template:WH Template:WS